Correspondence Brentuximab vedotin for CD30-positive tumours

According to a recent Review in The Lancet Oncology,1 only two antibody –drug conjugates have been approved by the US Food and Drug Administration (FDA)—brentuximab vedotin and ado-trastuzumab emtansine. Brentuximab vedotin was approved in 2011 and targets CD30-positive cells for the treatment of refractory Hodgkin’s lymphoma and anaplastic large-cell lymphoma. Rece ntly, 5-year follow-up results were reported for patients with refractory Hodgkin’s lymphoma showing that brentuximab vedotin had good disease control (41% overall survival and 22% progression-free survival; NCT00848926). (Source: The Lancet Oncology)

from #Cancer-Sfakianakis via simeraentaxei on Inoreader http://ift.tt/2cfH2E2
via IFTTT Medicine by Alexandros G.Sfakianakis,Anapafseos 5 Agios Nikolaos,Crete 72100,Greece,tel :00302841026182 & 00306932607174

Correspondence Brentuximab vedotin for CD30-positive tumours

Articles 30-day mortality after systemic anticancer treatment for breast and lung cancer in England: a population-based, observational study

Our findings show that several factors affect the risk of early mortality of breast and lung cancer patients in England and that some groups are at a substantially increased risk of 30-day mortality. The identification of hospitals with significantly higher 30-day mortality rates should promote review of clinical decision making in these hospitals. Furthermore, our results highlight the importance of collecting routine data beyond clinical trials to better understand the factors placing patients at higher risk of 30-day mortality, and ultimately improve clinical decision making. (Source: The Lancet Oncology)

from #Cancer-Sfakianakis via simeraentaxei on Inoreader http://ift.tt/2c5t8lO
via IFTTT Medicine by Alexandros G.Sfakianakis,Anapafseos 5 Agios Nikolaos,Crete 72100,Greece,tel :00302841026182 & 00306932607174

Articles 30-day mortality after systemic anticancer treatment for breast and lung cancer in England: a population-based, observational study

Cancer and Society Miss Sharon Jones

Partway through Barbara Kopple’s effervescent Miss Sharon Jones, the titular star revisits her hometown. North Augusta (SC, USA) was not an easy place to grow up, at least not if you were black. In 1952, just 3 years before Sharon Jones was born, the state legislature passed a phalanx of atrocious laws: no white child to be placed in the custody of a coloured person; steep financial penalties for white people who married those of a different race; cotton producers were forbidden from permitting different races to work alongside one another; and so forth. (Source: The Lancet Oncology)

from #Cancer-Sfakianakis via simeraentaxei on Inoreader http://ift.tt/2cfH2nw
via IFTTT Medicine by Alexandros G.Sfakianakis,Anapafseos 5 Agios Nikolaos,Crete 72100,Greece,tel :00302841026182 & 00306932607174

Cancer and Society Miss Sharon Jones

Cancer and Society Comedians deliver serious messages at Edinburgh Festival Fringe

Nudity is nothing new at the Edinburgh Festival Fringe (Edinburgh, UK), the world’s largest arts event, but few performers reach the point of stripping off as early in their shows as Australian stand-up Lana Schwarcz. Within moments of stepping on stage at the beginning of her set, Schwarcz unfastened her robe and stood with her breasts exposed to the audience. A digital projector then began casting the image of a florescent yellow crosshair onto her left breast, followed by a bright orange wash to imitate radiotherapy. (Source: The Lancet Oncology)

from #Cancer-Sfakianakis via simeraentaxei on Inoreader http://ift.tt/2c5txFb
via IFTTT Medicine by Alexandros G.Sfakianakis,Anapafseos 5 Agios Nikolaos,Crete 72100,Greece,tel :00302841026182 & 00306932607174

Cancer and Society Comedians deliver serious messages at Edinburgh Festival Fringe

Corrections Correction to Lancet Oncol 2016; 17: e335

Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 2016; 17: e328 –46—In table 4 of this Review, the label for the fourth row of IMWG MRD criteria should have read Imaging plus MRD-negative. This correction has been made to the online version as of Aug 30, 2016. (Source: The Lancet Oncology)

from #Cancer-Sfakianakis via simeraentaxei on Inoreader http://ift.tt/2cfI17j
via IFTTT Medicine by Alexandros G.Sfakianakis,Anapafseos 5 Agios Nikolaos,Crete 72100,Greece,tel :00302841026182 & 00306932607174

Corrections Correction to Lancet Oncol 2016; 17: e335

Cancer and Society A cancer novel

As a cancer novel, This Living and Immortal Thing triumphs. This debut book by oncologist Austin Duffy contains striking meditations on life and illness, none of them laced with truisms. While its writing has tremendous potential, its characters and central narrator are disappointingly flat. (Source: The Lancet Oncology)

from #Cancer-Sfakianakis via simeraentaxei on Inoreader http://ift.tt/2c5t0TG
via IFTTT Medicine by Alexandros G.Sfakianakis,Anapafseos 5 Agios Nikolaos,Crete 72100,Greece,tel :00302841026182 & 00306932607174

Cancer and Society A cancer novel

Correspondence Challenges in breast and cervical cancer control in Japan

We read with interest the Review by Sauvaget and colleagues1 on challenges to prevent breast and cervical cancer in Japan, and their proposed recommendations to overcome them. While we wholeheartedly agree with all the recommendations put forward, we would like to suggest two more —namely, the inclusion of human papillomavirus (HPV) self-sampling in screening programmes for non-responders, and a school-based cervical cancer education programme. (Source: The Lancet Oncology)

from #Cancer-Sfakianakis via simeraentaxei on Inoreader http://ift.tt/2cfIaaJ
via IFTTT Medicine by Alexandros G.Sfakianakis,Anapafseos 5 Agios Nikolaos,Crete 72100,Greece,tel :00302841026182 & 00306932607174

Correspondence Challenges in breast and cervical cancer control in Japan